Brand product · Tirzepatide
Mounjaro: FDA Status, Uses, Safety and Cost
Two receptor targets (GIP + GLP-1)
What Mounjaro is
Mounjaro is Eli Lilly’s brand of tirzepatide approved for type 2 diabetes — NOT for weight management. The same active ingredient is approved for chronic weight management and obstructive sleep apnea under the brand Zepbound.
Key facts
| Generic (active ingredient) | Tirzepatide |
|---|---|
| Brand names | Mounjaro |
| Drug class | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company |
| FDA status | FDA Approved for a Different IndicationNot approved for weight management |
| Administration | Subcutaneous injection (prefilled pen) |
| Frequency | Once weekly |
| Approval date | May 2022 |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Mounjaro is approved for
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Not approved for weight management
Mounjaro is FDA approved, but weight management is not among its approved indications. Prescribing it for weight loss is off-label — a decision between a patient and their clinician — and insurers generally do not cover it for that purpose.
How Mounjaro works
Tirzepatide activates GIP and GLP-1 receptors, improving blood-sugar control in type 2 diabetes; it also reduces appetite and body weight, which led to the separate Zepbound approval for weight management.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Mounjaro is given by subcutaneous injection (prefilled pen), once weekly.
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia (indigestion)
- Abdominal pain
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Mounjaro is a brand product containing the active ingredient tirzepatide.
Cost and access
- Prescription only, for its approved diabetes indication.
- Lilly offers a Mounjaro savings card for eligible commercially insured patients with type 2 diabetes; terms change — verify on the official site.
- Weight-loss use of Mounjaro is off-label; insurers generally do not cover it for that purpose.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Commonly covered for type 2 diabetes with prior authorization confirming the diagnosis.
- For weight management, the on-label product is Zepbound — plans typically direct weight-management coverage (if any) there.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is Mounjaro approved for weight loss?
- No. Mounjaro is FDA approved for type 2 diabetes. Tirzepatide is approved for chronic weight management under the brand name Zepbound.
- What is the difference between Mounjaro and Zepbound?
- Same active ingredient (tirzepatide), same manufacturer, different approved uses: Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea. See our full comparison.
Related guides
Sources
- Mounjaro prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- Drugs@FDA database — FDA. Link last verified August 12, 2026.
- Mounjaro official site (Eli Lilly) — Manufacturer. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.